Are you ready to join a team committed to making a meaningful impact on cancer treatment through the discovery and development of precision medicines? At Kura Oncology, you have an opportunity to be a part of something bigger, with a lasting impact that you can be proud of.

At Kura Oncology, we are working to change the paradigm and improve the science of cancer treatment. As an organization, we strive to cultivate a diverse and talented professional culture driven to develop precision medicine therapeutics.

As we continue to build a leading biotech organization with a strong culture, a patient-focused mindset and a team focused on relentless execution, we are looking for innovative, passionate professionals to join us and make our vision a reality.

To succeed at Kura, you will need to have a demonstrated ability for excellence in drug discovery and development and a roll-up your sleeves attitude. The ideal candidate will possess a values-driven work style where integrity and grit drive all behaviors, decisions, and actions.

ESSENTIAL JOB FUNCTIONS:

We’re looking for a Vice President, Clinical Development (MD) to lead cross-functional clinical teams for the design and conduct of clinical studies. This position will report to the Chief Medical Officer.

Lead cross-functional clinical teams for the design and conduct of oncology studies, specifically within the Darlifarnib franchise.
Serve as the Clinical Development Lead on the Global Program Team, driving development strategy and driving integrated cross-functional decision-making across the lifecycle of the program.
Ensure that scientific rigor and innovation drives Kura Oncology’s development strategies.
Ensure excellence in both strategy and execution by partnering closely with colleagues in clinical operations, biostatistics, data management, program management and translational medicine.
Serve as Medical Monitor of sponsored clinical research and as medical representative to CROs, reference laboratories and other organizations involved in the execution of clinical trials.
Responsible for of all clinical regulatory deliverables and other clinical documents associated with the clinical trials under his/her direct responsibility, including protocols, and the clinical portion of INDs, CTAs, investigator brochures, CRF’s, annual IND reports, CSR’s and clinical expert reports, among others.
Responsible for the analysis of clinical data, including safety monitoring in collaboration with PV.
Participate in site initiation visits and other site visits at clinical center.

JOB QUALIFICATIONS:

Minimum of 10 years of relevant experience in drug development either in industry (preferred) or in academia. M.D. degree required.
Proven track record of strong clinical research skills, including publications.
Ability to partner with others to implement innovative development strategies.
Experience in precision oncology/hematology preferred.
Demonstrated excellence in independently leading and conducting research and ability to evaluate, interpret and present complex scientific data.
Demonstrated written and excellent communication and interpersonal skills, with the ability to translate statistical concepts into layman's terms.
Strong attention to detail with ability to understand the broader picture and priorities.
Must be a dedicated self-starter with a high energy level and ability to achieve results.
Must have strong communication and leadership skills-the ability to influence and work successfully with colleagues, customers, and corporate partners.
The candidate should have experience in handling multiple projects at a time.
Some travel may be required when appropriate.

The base range for a Vice President is $397,000 - $450,000 per year. Individual pay may vary based on additional factors, including, and without limitation, job-related skills, experience, work location, and relevant education or training. Kura's compensation package also includes generous benefits, equity, and participation in an annual target bonus.

#LI-RM1

Kura’s Values that are used for candidate selection and performance assessments:

We work as one for patients
We are goal-focused and deliver with excellence
We are science-driven courageous innovators
We strive to bring out the best in each other and ourselves

The Kura Package

Career advancement/ development opportunities
Competitive comp package
Bonus
401K + Employer contributions
Generous stock options
ESPP Plan
20 days of PTO to start
18 Holidays (Including Summer & Winter Break)
Generous Benefits Package with a variety of plans available with a substantial employer match
Paid Paternity/Maternity Leave
In-Office Catered lunches
Home Office Setup
Lifestyle Spending Stipend
Commuter Stipend (Boston Office)
Regular employee social activities, including happy hours, monthly birthday celebrations, Kura Koffee Talks, and much more!

Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company’s pipeline consists of small molecule drug candidates designed to target cancer signaling pathways. Ziftomenib, a once-daily, oral menin inhibitor, is the first and only investigational therapy to receive Breakthrough Therapy Designation from the U.S. Food and Drug Administration (“FDA”) for the treatment of relapsed/refractory (“R/R”) NPM1-mutant acute myeloid leukemia (“AML”). In November 2024, Kura Oncology entered into a global strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize ziftomenib for AML and other hematologic malignancies. Enrollment in a Phase 2 registration-directed trial of ziftomenib in R/R NPM1-mutant AML has been completed, and in the second quarter of 2025, the companies announced the FDA’s acceptance of a New Drug Application for ziftomenib for the treatment of adult patients with R/R NPM1-mutant AML and assignment of a Prescription Drug User Fee Act target action date of November 30, 2025. Kura Oncology and Kyowa Kirin are also conducting a series of clinical trials to evaluate ziftomenib in combination with current standards of care in newly diagnosed and R/R NPM1-mutant and KMT2A-rearranged AML. KO-2806, a next-generation farnesyl transferase inhibitor, is being evaluated in a Phase 1 dose-escalation trial as a monotherapy and in combination with targeted therapies for patients with various solid tumors. Tipifarnib, a potent and selective farnesyl transferase inhibitor, is currently in a Phase 1/2 trial in combination with alpelisib for patients with PIK3CA-dependent head and neck squamous cell carcinoma. For additional information, please visit Kura’s website at www.kuraoncology.com and follow us on X and LinkedIn.

Kura Oncology is committed to creating a diverse environment and is proud to be an equal opportunity employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, gender, gender identity or expression, sexual orientation, national origin, genetics, disability, age, or veteran status.

If you are a California resident, please see the attached Privacy Notice CA Privacy Notice

Vice President, Clinical Development

AI overview

Perks & Benefits Extracted with AI